Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units
SEC Form 4 Filing
Director Douglas S. Ingram acquired 38,396 shares of Arrowhead Pharmaceuticals through restricted stock units that will vest in three years.
Summary
- On February 6, 2025, Douglas S. Ingram, a director of Arrowhead Pharmaceuticals, acquired 38,396 shares of common stock.
- The acquisition was in the form of restricted stock units, granted on February 6, 2025, which will vest in three years.
- The price of the acquired shares was $20.09 per share.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring shares suggests confidence, but it's a standard transaction.
Positives
- The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Director share acquisitions are common and can be seen as a positive signal, aligning management's interests with those of shareholders.
Stakeholder Impact
- The acquisition of shares by a director may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of transaction and grant date of restricted stock units. |
| 02/07/2025 | Date of signature on the Form 4 filing. |
Keywords
Arrowhead Pharmaceuticals, Director, Share Acquisition, Restricted Stock Units, Form 4, ARWR, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.